anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Primary open angle glaucoma (POAG) is defined as a "genetically complex trait", where modifying factors act on a genetic predisposing background. For the majority of glaucomatous conditions, DNA variants are not sufficient to explain pathogenesis. Some genes are clearly underlying the more "Mendelian" forms, while a growing number of related polymorphisms in other genes have been identified in recent years. Environmental, dietary, or biological factors are known to influence the development of the condition, but interactions between these factors and the genetic background are poorly understood. Several studies conducted in recent years have led to evidence that epigenetics, that is, changes in the pattern of gene expression without any changes in the DNA sequence, appear to be the missing link. Different epigenetic mechanisms have been proven to lead to glaucomatous changes in the eye, principally DNA methylation, post-translational histone modification, and RNA-associated gene regulation by non-coding RNAs. The aim of this work is to define the principal epigenetic actors in glaucoma pathogenesis. The identification of such mechanisms could potentially lead to new perspectives on therapeutic strategies.
A moisture-free matrix for oral products and application thereof, belonging to the technical field of oral products. The moisture-free matrix is characterized in that: one or both of a peroxide source and a cationic antibacterial agent added into the matrix of the oral product can stably exist, and the matrix consists of propylene glycol, fumed silica and polyvinylpyrrolidone in a weight ratio of 1: 0.03-0.15: 0.01-0.08. The cationic antibacterial agent may be quaternary ammonium salt or guanidine antibacterial agent, such as ammonium didecyldimethyloxyprolinate (PODA) or cetylpyridinium chloride. The peroxide source may be urea peroxide or calcium peroxide, or percarbonate, or perborate, or hydrogen peroxide, or a polyvinylpyrrolidone hydrogen peroxide complex. The moisture-free matrix is used for preparing products for removing oral biomembranes. The invention solves a key technical difficulty that a peroxide source and a cationic antibacterial agent can stably coexist and synergistically inhibit and destroy a biological membrane in the same system.
A method for fermenting Artemisia princeps var. orientalis is provided to be able to efficiently extract medicinal ingredients of the Artemisia princeps var. orientalis. The method comprises the steps of: (a) after separating leaves and stems of naturally harvested Artemisia princeps var. orientalis or Artemisia princeps var. orientalis dried at a shady spot, collecting the leaves; (b) spraying water to the leaves; (c) charging a container with the water-smeared Artemisia princeps var. orientalis leaves; (d) covering the container with a lid to seal it and sealing the surrounding of the container; (e) putting the sealed container at the outdoor to ferment the stored leaves; and (f) opening the lid of the sealed container when the inner temperature of the fermented leaves is measured as 30-80 deg.C; and (g) taking the fermented leaves out of the container and then drying it in a place where there is no direct rays of the sun and air is well circulated for 1-3 days.
BACKGROUND Statin-induced myopathy can present with symptoms ranging from mild myalgia to significant muscle weakness. Muscle-related adverse effects of statins have been very challenging in clinical practice and they necessitate high clinical suspicion. This case report highlights how statin-induced autoimmune myopathy often goes undiagnosed. CASE REPORT We present a 69-year-old man with a past medical history of coronary artery disease who presented with myalgia and progressive proximal muscle weakness for 2 months, with a creatinine kinase of 8323 U/L. Atorvastatin was held on admission and the patient received intravenous (IV) fluid as treatment for presumed rhabdomyolysis. Although CK was trending down, he did not show significant improvement in muscle weakness or myalgia. At this point, myositis was suspected, so a myositis panel including anti-HMG Co-A reductase antibody was ordered and he was started on IV steroids. Anti-HMG Co-A reductase antibody was positive, and the rest of myopathy workup was negative. Meanwhile, the patient's muscle weakness significantly improved with IV steroid. He was discharged on methylprednisolone with close outpatient rheumatology follow-up. CONCLUSIONS Muscle-related adverse effects of statins, including rhabdomyolysis and myopathy, can fail to respond to conservative management. It is crucial to identify and manage statin-induced autoimmune myopathy as a possible differential diagnosis in patients with muscle weakness and elevated CK while on statin therapy who do not respond to intravenous fluid alone.
Xanthogranulomatous cholecystitis is a rare chronic inflammatory disease of the gallbladder associated with complications such as perforation, dense adhesions and fistulation. We present a case of a female patient in her 20s who presented with three episodes of recurrent cholecystitis over 3 months. Her medical history included an endoscopic retrograde cholangiopancreatography for obstructive jaundice due to choledocholithiasis. As there was no possibility of performing an urgent cholecystectomy during her initial admission, she was listed for an elective operation. Laparoscopic inspection revealed a pericholecystic mass involving the omentum, transverse colon, duodenum and liver and findings suspicious of a cholecystoappendiceal fistula. Laparoscopic cholecystectomy and appendicectomy were performed. Early index admission laparoscopic cholecystectomy should be performed in patients with acute cholecystitis to prevent higher grades of operative difficulty and associated complications. This case presentation-cholecystoappendiceal fistula associated with xanthogranulomatous cholecystitis-emphasises the necessity of complying with national guidelines in managing acute calculous cholecystitis.
In the United States during 2007, \~ 213,380 people were expected to be diagnosed with lung cancer, and \~ 160,390 expected to die of the disease. Among those diagnosed with lung cancer, 79% to 90% are cigarette smokers. Overall, \~21% of adults in the U.S. smoke. The most important and cost-effective strategy for the prevention of lung cancer mortality is smoking avoidance and cessation. Smoking cessation is often difficult for smokers to achieve for a variety of reasons including: difficulty with nicotine withdrawal, failure to perceive the benefits of smoking cessation, and failure to perceive the risks associated with smoking. We argue that the most effective biomarkers to affect perceptions of harm, especially for lung cancer, are those that signal progression towards disease development. Prior to the development of lung cancer, there are genetic alterations in the bronchial epithelium. One such alteration is the methylation of the promoter region of Rb-p16 (p16) important in regulation of the G1-S transition of the cell cycle. Prior studies have shown that presence of the promoter methylation of p16 results in a 2-fold increase in risk of developing lung cancer in smokers with evidence of airway obstruction.

Proposed is a pilot study of educating smokers about the role of genetics and lung cancer in Durham VA out-patient clinics. The goal of this pilot study is to assess the interest in study participation from the VA smoking population, as well as to determine the fraction of subjects who will complete the study to power a future larger trial. Interested patients will receive a 15 minute educational presentation on the function of p16 and its role in development of lung cancer. They will then be assessed for airway obstruction by hand-held spirometry followed by review of a questionnaire assessing their understanding of the presented information, their concern for developing lung cancer, and their desire to quit smoking. All patients will be offered smoking cessation assistance at this point. Enrolled patients will then be given 3 sputum cups to take home and return with morning sputum samples by mail. Samples will be assessed for evidence of p16 methylation and patients will be informed of the results. Follow-up phone interviews will be performed at 2 to 4 weeks after patients have received their results by mail to assess their understanding of the results, and their desire to stop smoking. A final phone interview will occur approximately 3 months after the sputum testing to assess attempts to stop smoking as well as the patients continued understanding of their test results. Patients will be compensated a total of $40.00 for completing the study. For purposes of this pilot, we are interested primarily in the descriptive statistics (e.g., frequencies) associated with the outcome of each objective (e.g., how many expressed interest, how many returned the sputum samples).
Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: "STOP MIP", which is a cohort of pregnant women followed up until delivery and the "Baby-Cohort study", which enrols babies from mothers in the "STOP MIP" trial and follows them until their first year of live. When participants of the "Baby-cohort Study" reach study end, they are offered to participate in this study.
An evidence map was established to comprehensively sort out the clinical research in the treatment of post-acute myocardial infarction heart failure(P-AMI-HF) with Chinese patent medicines, so as to reveal the distribution of evidence in this field. CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, and EMbase were searched for the randomized controlled trial(RCT), systematic reviews/Meta-analysis, and guidelines/consensus in this field. The evidence was analyzed and displayed in the form of a combination of text, charts, bubble charts, and bar charts, and the quality of RCT, systematic reviews/Meta-analysis, and guidelines/consensus were evaluated by RoB 1.0, AMSTAR2, and AGREE Ⅱ, respectively. A total of 163 RCTs, 4 systematic reviews/Meta-analysis, 1 network Meta-analysis, 2 observational studies, and 5 guidelines/consensus were included. In recent years, the total number of publications in this field has shown an upward trend. There were a variety of Chinese patent medicines in the treatment of P-AMI-HF, among which Shenfu Injection received the most attention. The clinical RCT and systematic reviews/Meta-analysis generally had poor quality, and the RCT mostly had a small size, a single center, and a short cycle. The outcome indicators mainly included cardiac function indicators, myocardial injury markers, total response rate, hemodynamic indicators, and safety indicators, while the characteristic efficacy indicators of TCM received insufficient attention. The development processes of some guidelines/consensus lack standardization, which compromised their authority and rationality. Chinese patent medicines have advantages in the treatment of P-AMI-HF, while there are also problems, which remain to be solved by more high-quality evidence. That is, more large-sample and multi-center clinical studies should be carried out in the future, and the formulation process of relevant systematic reviews/Meta-analysis and guideline/consensus should be standardized and the quality of evidence should be improved. In this way, the effectiveness and safety of Chinese patent medicines in the treatment of P-AMI-HF can be explored.
Glutamate-mediated excitotoxicity has been extensively explored as a therapeutic target for the development of potential treatments of neurological disorders including stroke. However, the effect of glutamate on astrocytes under pathological conditions has been less studied. Using primary astrocyte culture, we determined the effect of glutamate on astrocytes against ischemic insult. Glutamate provided a cytoprotective effect and acted as an alternative substrate for ATP production in primary astrocytes against oxygen glucose deprivation reoxygenation insult, which was blocked by glutamate uptake inhibition. The cytoprotective effect of glutamate appears to be astrocyte-specific, as glutamate dose-dependently induces cytotoxic action in murine hippocampal HT-22 cell line. Interestingly, the cytoprotective effect of glutamate against glucose deprivation was short-last, as no protection was observed after 3-day glucose deprivation. We determined the metabolic phenotype of primary astrocyte cultured in glucose or glutamate. Primary astrocytes cultured in glutamate displayed a different metabolic phenotype when compared to those cultured in glucose, evidenced by higher basal and maximal oxygen consumption rate (OCR), higher ATP production and proton leak-coupled OCR, as well as lower glycolysis. Furthermore, glutamate exposure resulted in astrocyte activation, evidenced by an increase in astrocyte size and GFAP expression. Our study demonstrated that glutamate exerts a dual effect on astrocytes under ischemic condition. Glutamate provides an alternative substrate for energy metabolism in the absence of glucose, thereby protecting astrocytes against ischemic insults. On the other hand, glutamate exposure induces astrogliosis. Modulation of glutamate uptake and metabolism in astrocytes may provide novel targets for alleviating ischemic injury and improving function recovery after ischemic stroke.
Fibrotic diseases are characterized by the uncontrolled accumulation of extracellular matrix (ECM) components leading to disruption of tissue homeostasis. Myofibroblasts as the main ECM-producing cells can originate from various differentiated cell types after injury. Particularly, the process of endothelial-to-mesenchymal transition (endMT), describing phenotypic shifts of endothelial cells to adopt a fully mesenchymal identity, may contribute to the pool of myofibroblasts in fibrosis, while leading to capillary rarefaction and exacerbation of tissue hypoxia. In renal disease, incomplete recovery from acute kidney injury (AKI) and the ensuing fibrotic reaction stand out as major contributors to chronic kidney disease (CKD) development. While the focus has largely been on impaired tubular epithelial repair as a potential fibrosis-driving mechanism, alterations in the renal microcirculation post-AKI, and in particular endMT as a maladaptive response, could hold equal significance. Dysfunctional interplays among various cell types in the kidney microenvironment can instigate endMT. Transforming growth factor beta (TGF-β) signaling, with its downstream activation of canonical/Smad-mediated and non-canonical pathways, has been identified as primary driver of this process. However, non-TGF-β-mediated pathways involving inflammatory agents and metabolic shifts in intercellular communication within the tissue microenvironment can also trigger endMT. These harmful, maladaptive cell-cell interactions and signaling pathways offer potential targets for therapeutic intervention to impede endMT and decelerate fibrogenesis such as in AKI-CKD progression. Presently, partial reduction of TGF-β signaling using anti-diabetic drugs or statins may hold therapeutic potential in renal context. Nevertheless, further investigation is warranted to validate underlying mechanisms and assess positive effects within a clinical framework.
Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
The invention discloses a kind of special siRNA suppressing p21 gene expression and application thereof, does is the siRNA of special suppression p21 gene expression by SEQ? ID? NO.1 and SEQ? ID? the double-stranded RNA of the composition of nucleotide sequence shown in NO.2; It is modified RNA after the modification obtained; In vitro tests, it is shown that RNA provided by the invention can suppress p21 gene expression in differential high efficient ground, reduces fat and drips and suppress the deposition of triglyceride. Present invention could apply to the study of incident mechanism of non-alcohol fatty liver and the potential treatment of non-alcoholic fatty liver disease. The present invention has important value.
A method for reducing skin staining during hair colouring, comprising the following steps in sequence; applying a colouring agent to the hair, allowing the colouring agent to act for 30 seconds to 45 minutes, applying an undiluted cleaning agent to skin that can come into contact with the colouring agent when the latter is washed out, jointly washing out the colouring and cleaning agents; wherein the colouring agent contains at least one oxidation dye precursor and/or direct dye and the cleaning agent contains at least one anionic surfactant. Preferably, the pH of the cleaning agent is at least 1.5 units higher than that of the colouring agent. The surfactant may be sodium laureth sulfate. The hair dye may be applied with an applicator, brush, comb etc. Also disclosed is a multicomponent packaging unit, comprising, packaged separately, an aqueous colouring agent containing at least one oxidation dye precursor and/or direct dye and an aqueous cleaning agent containing at least one anionic surfactant; wherein the pH of the cleaning agent differs by at least 1.5 units from that of the colouring agent. The method of the invention minimises skin staining and removes the need to use gloves in the hair dyeing process.
Using a training device, two conductive clips are placed securely on both the left and right tragus areas of the outer ear. Using parameters we have identified through systematic review, electrical stimulation (pulse width:200μs; frequency:30Hz) is initiated at 10mA, until the participant feels a 'tingling' sensation within 20s of commencing. At this point the current is reduced to a level just below this perceptible threshold (20-60 mA), which is defined as the 'prescription dose'. The participant then receives another active device set at the 'prescription dose'.
Patients will take oral tablets of Placebo for 26 weeks. The dose strength may be titrated within 6 weeks.
This is a cluster randomized controlled trial. Teachers were randomized within schools to the treatment and control conditions. To assess the impact of offering TOP®, students were surveyed three times: at baseline, before the intervention began for the treatment group; 12 months after baseline (short-term impacts); and 24 months after baseline (long-term impacts). Baseline data and subsequent follow-up data were collected using a Web-based survey. Paper surveys were used as back-up for baseline data collection. The pooled survey data from two school-year cohorts (school years 2011-2012 and 2012-2013) were used to estimate program impacts using an intent-to-treat (ITT) analysis. Program fidelity and interview data were used to describe program implementation.TOP® was delivered in middle schools, high schools, alternative schools, and public charter schools in Hennepin County. It was implemented during school hours in classes that spanned an entire school year with the same cohort of students. The subject of the class in which TOP® was placed differed across schools (for example, social studies, study hall, health).
The present invention relates to a psychotherapeutic device capable of measuring brain waves, which comprises: a body; a band for wearing the body on a face; and a cushioning material combined with an inner surface of the body. The body has a manipulation button for manipulating an operation of a device, a voice output means for outputting a voice signal, and an LED bar at a position corresponding to eyes of a user. The LED bar has a first LED row disposed at a position corresponding to a left eye of the user and a second LED row disposed at a position corresponding to a right eye of the user. A protective film is provided on a side surface corresponding to the eyes of the user of the LED bar. The protective film includes an anti-reflective film and a window film. The psychotherapeutic device of the present invention further comprises: a brain wave measuring sensing means including a pair of brain wave measuring electrodes and a grounding electrode, which are installed at both eye parts of an inner surface of the body where the LED bar is installed to measure a brain wave which is a kind of a bio-signal; and a USB interface coupled to a personal computer or a smartphone. The psychotherapeutic device of the present invention is connected to the personal computer or smartphone, and operates brain waves of a user in accordance with a measurement request signal using the smartphone to transmit a brain wave signal sensed by the personal computer or smartphone.
An isolated gene cluster of Micromonospora echinospora which codes for calicheamicin biosynthesis. The biosynthetic gene cluster contains genes encoding for proteins and enzymes used in the biosynthetic production of calicheamicin, including the aryltetrasaccharide and aglycone. The gene cluster also includes the gene conferring calicheamicin resistance. The invention also provides isolated genes of the biosynthetic cluster and their corresponding proteins. In addition, the invention relates to DNA hybridizing with the calicheamicin gene cluster and the isolated genes of that cluster.  Expression vectors containing genes of the biosynthetic gene and their functional variants are also provided. The invention also relates to host cells conjugated with DNA isolated from the Micromonospora echinospora spp.  calichensis genome.
PROBLEM TO BE SOLVED: To prepare a dental pretreating agent capable of carrying out both the bonding of a dentinal part to a restorative material and the bonding of an enamel to the restorative material by dissolving a specific inorganic acid salt in an acidic aqueous solution. SOLUTION: This dental pretreating agent is obtained by using an acidic aqueous solution at pH<=3.5 prepared by dissolving a phosphate therein. For example, calcium phosphate, iron phosphate, potassium phosphate and sodium phosphate can be cited as the phosphate and, among them, the calcium phosphate is preferred. The concentration thereof in the acidic aqueous solution is preferably 0.1-20wt.%. For example, phosphoric acid, hydrochloric acid and nitric acid can be cited as the acid in the acidic aqueous solution. The amount of the compounded acid is preferably 1-65wt.%. An adhesive can directly be applied to teeth treated with the pretreating agent without applying any primer thereto.
FIELD: medicine, oncology. SUBSTANCE: invention relates to prophylaxis and treatment of hematological complications of chemotherapy and radiation therapy. Method involves administration in patient 100-200 mg of ceruloplasmin in 200 ml of isotonic sodium chloride solution by intravenous drop route at the rate 30 drops per a minute every day for 5-7 days. Preparation is effective both before chemotherapy carrying out and with its simultaneous combination. EFFECT: enhanced effectiveness of treatment and prophylaxis of cytostatic and postradiation leukopenia. 2 tbl, 2 ex